Table 1. Association of baseline characteristics to NLR or PLR.
| Variable | N (%) (n=67) | NLR, n (%) | PLR, n (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Low (n=45) | High (n=22) | P value | Low (n=19) | High (n=48) | P value | |||
| Age (years) | 0.516 | 0.610 | ||||||
| ≤50 | 25 (37.3) | 18 (72.0) | 7 (28.0) | 8 (32.6) | 17 (68.0) | |||
| >50 | 42 (62.7) | 27 (64.3) | 15 (35.7) | 11 (26.2) | 31 (73.8) | |||
| Histologic type | 0.624 | 0.169 | ||||||
| Ductal | 62 (92.5) | 41 (66.1) | 21 (33.9) | 16 (25.8) | 46 (74.2) | |||
| Lobular | 1 (1.5) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | |||
| Others | 4 (6.0) | 3 (75.0) | 1 (25.0) | 2 (50.0) | 2 (50.0) | |||
| Grade | 0.087 | 0.269 | ||||||
| G1 | 6 (9.0) | 6 (100.0) | 0 (0.0) | 3 (50.0) | 3 (50.0) | |||
| G2 | 42 (62.7) | 29 (69.0) | 13 (31.0) | 12 (28.6) | 30 (71.4) | |||
| G3 | 15 (22.4) | 8 (53.3) | 7 (46.7) | 4 (26.7) | 11 (73.3) | |||
| Unknowna | 4 (6.0) | 2 (50.0) | 2 (50.0) | 0 (0.0) | 4 (100.0) | |||
| Ki-67 | 0.034* | 0.179 | ||||||
| <14% | 7 (10.4) | 2 (28.6) | 5 (71.4) | 4 (57.1) | 3 (42.9) | |||
| ≥14% | 60 (89.6) | 43 (71.7) | 17 (28.3) | 15 (25.0) | 45 (75.0) | |||
| HR | 0.545 | 0.846 | ||||||
| Positive | 34 (50.7) | 24 (70.6) | 10 (29.4) | 10 (29.4) | 24 (70.6) | |||
| Negative | 33 (49.3) | 21 (63.6) | 12 (36.4) | 9 (27.3) | 24 (72.7) | |||
| Molecular subtype | 0.633 | 0.028* | ||||||
| Luminal A | 8 (11.9) | 5 (62.5) | 3 (37.5) | 1 (12.5) | 7 (87.5) | |||
| Luminal B/HER2− | 13 (19.4) | 11 (84.6) | 2 (15.4) | 8 (61.5) | 5 (38.5) | |||
| Luminal B/HER2+ | 13 (19.4) | 8 (61.5) | 5 (38.5) | 1 (7.7) | 12 (92.3) | |||
| HER2 enriched | 21 (31.3) | 13 (61.9) | 8 (38.1) | 6 (28.6) | 15 (71.4) | |||
| Triple negative | 12 (17.9) | 8 (66.7) | 4 (33.3) | 3 (25.0) | 9 (75.0) | |||
*, significant values; a, unknown, not included in the analysis. HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.